Adding Streptomycin to an Intensified Regimen for Tuberculous Meningitis Improves Survival in HIV-Infected Patients

Interdisciplinary Perspectives on Infectious Diseases
Gerardo Alvarez-UriaPraveen Kumar Naik

Abstract

In low- and middle-income countries, the mortality of HIV-associated tuberculous meningitis (TM) continues to be unacceptably high. In this observational study of 228 HIV-infected patients with TM, we compared the mortality during the first nine months of patients treated with standard antituberculosis therapy (sATT), intensified ATT (iATT), and iATT with streptomycin (iATT + STM). The iATT included levofloxacin, ethionamide, pyrazinamide, and double dosing of rifampicin and isoniazid and was given only during the hospital admission (median 7 days, interquartile range 6-9). No mortality differences were seen in patients receiving the sATT and the iATT. However, patients receiving the iATT + STM had significant lower mortality than those in the sATT group (hazard ratio [HR] 0.47, 95% confidence interval [CI] 0.24 to 0.93). After adjusting for other covariates, the mortality hazard of the iATT + STM versus the sATT remained statistically significant (adjusted HR 0.2, 95% CI 0.09 to 0.46). Other factors associated with mortality were previous ATT and low albumin concentrations. The mortality risk increased exponentially only with CD4+ lymphocyte concentrations below 100 cells/μL. In conclusion, the use of iATT resulted in a clinic...Continue Reading

Associated Clinical Trials

May 27, 2015·Gerardo Alvarez-Uria

References

Jan 1, 1991·Clinical Pharmacology and Therapeutics·S KaojarernS Krittiyanunt
Sep 1, 1993·The American Review of Respiratory Disease·G A EllardB W Allen
Feb 16, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·G ThwaitesJ Farrar
Jan 10, 2003·American Journal of Respiratory and Critical Care Medicine·Amina JindaniDenis A Mitchison
Apr 30, 1960·British Medical Journal·J LORBER
Jun 9, 2005·The Journal of Infectious Diseases·Guy E ThwaitesJeremy J Farrar
Sep 9, 2010·The Lancet Infectious Diseases·Suzaan MaraisBen J Marais
Feb 6, 2015·American Journal of Respiratory and Critical Care Medicine·Martin J BoereeUNKNOWN PanACEA Consortium
Feb 24, 2015·International Journal of Antimicrobial Agents·Lindsey Te BrakeRob Aarnoutse

❮ Previous
Next ❯

Citations

Sep 2, 2016·The Cochrane Database of Systematic Reviews·Sophie JullienRohit Bhatia

❮ Previous
Next ❯

Software Mentioned

Stata

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.